No quarterly revenue total was found in Raphael Pharmaceutical Inc.'s SEC filings.
Raphael Pharmaceutical Inc. (RAPH) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products.
Revenue
—
Net income
$-223,000
+30.7% vs year-ago quarter
Operating cash flow
$0
+100.0% vs year-ago quarter
Free cash flow
—
EPS
$0.01
-50.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
20.18M
+2.8% vs year-ago quarter
Net cash
$-22,000
Q4 FY2024
Operating margin
—
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RAPH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1415397
- Former names
- Easy Energy Inc (until May 14, 2021)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$199,000 | -$223,000 | -$254,000 | -$251,000 | -$315,000 |
| Net income | -$223,000 | -$229,000 | -$273,000 | -$255,000 | -$322,000 |
| Diluted EPS | $0.01 | $0.01 | -$0.01 | $0.01 | $0.02 |
| Operating cash flow | $0 | -$44,000 | $46,000 | -$17,000 | -$30,000 |
| Total assets | $7,000 | $3,000 | $53,000 | $7,000 | $30,000 |
| Stockholders' equity | -$1.9M | -$1.7M | -$1.4M | -$1.3M | -$1.0M |
| Cash and investments | $1,000 | $1,000 | $45,000 | $3,000 | $20,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 1, 2026 | Jul 30, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 17, 2026 | Jul 16, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 24, 2026 | Dec 31, 2025 |
All 179 Raphael Pharmaceutical Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.